These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 25963886)
1. Acute myeloid leukemia in the vascular niche. Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886 [TBL] [Abstract][Full Text] [Related]
2. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796 [TBL] [Abstract][Full Text] [Related]
3. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Wang A; Zhong H Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132 [TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis in patients with hematologic malignancies]. Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Vijay V; Miller R; Vue GS; Pezeshkian MB; Maywood M; Ast AM; Drusbosky LM; Pompeu Y; Salgado AD; Lipten SD; Geddes T; Blenc AM; Ge Y; Ostrov DA; Cogle CR; Madlambayan GJ Leuk Res; 2019 Sep; 84():106180. PubMed ID: 31299413 [TBL] [Abstract][Full Text] [Related]
6. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A; Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530 [TBL] [Abstract][Full Text] [Related]
8. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862 [TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275 [TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Ladikou EE; Chevassut T; Pepper CJ; Pepper AG Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579 [TBL] [Abstract][Full Text] [Related]
11. Targeting the microenvironment in acute myeloid leukemia. Rashidi A; Uy GL Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001 [TBL] [Abstract][Full Text] [Related]
13. Role of Microenvironment in Resistance to Therapy in AML. Tabe Y; Konopleva M Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386 [TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. Skelding KA; Barry DL; Theron DZ; Lincz LF Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005 [TBL] [Abstract][Full Text] [Related]
15. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells. Brenner AK; Andersson Tvedt TH; Bruserud Ø Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732 [TBL] [Abstract][Full Text] [Related]
16. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063 [TBL] [Abstract][Full Text] [Related]
17. RNA trafficking by acute myelogenous leukemia exosomes. Huan J; Hornick NI; Shurtleff MJ; Skinner AM; Goloviznina NA; Roberts CT; Kurre P Cancer Res; 2013 Jan; 73(2):918-29. PubMed ID: 23149911 [TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049 [TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells and their vascular niche: Do they benefit from each other? Ping YF; Zhang X; Bian XW Cancer Lett; 2016 Oct; 380(2):561-567. PubMed ID: 25979233 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor signaling in acute myeloid leukemia. Kampen KR; Ter Elst A; de Bont ES Cell Mol Life Sci; 2013 Apr; 70(8):1307-17. PubMed ID: 22833169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]